cirrhosis

liver
Biotech

BioVie plans $20M IPO for spinout developing liver disease drug

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market.
James Waldron Mar 17, 2026 5:18am
pass the torch deal sell buy acquisition

Gilead pays $4.3B for CymaBay's late-stage liver disease med

Feb 12, 2024 9:01am
liver NASH NAFLD

Akero sinks as midphase cirrhosis fail sparks flash NASH crash

Oct 10, 2023 8:00am
plan B fail reroute road path trail miss

Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver

Aug 15, 2023 7:30am
Pliant Therapeutics

Novartis bets $80M on Pliant's preclinical NASH prospect

Oct 23, 2019 8:00am
Headshot of Aoife Brennan CEO of Synlogic

Synlogic scraps ammonia-lowering drug after early phase fail

Aug 20, 2019 8:08am